High risk pulmonary embolism in oncology
Journal Title: OncoReview - Year 2011, Vol 1, Issue 2
Abstract
Pulmonary embolism is a frequent complication of both cancer and the oncologic therapy. There is still discussed the subject of optimal antithrombotic prophylaxis in oncology. This article presents the patient with metastatic prostate cancer who experienced complications during therapy with lenalidomideand docetaxel. The doctors from emergency department diagnosed in this patient neutropenic fever with suspicion of pneumonia and pleuritis. Meanwhile the diagnostic scheme proceeded in the Department of Oncology according to the guidelines of European Society of Cardiology helped to diagnose high risk pulmonary embolism. The article presents a case report of effective multi-disciplinary diagnosis and treatment of oncological patients with complications after chemotherapy. The discussion includes current obligatory recommendations of the American and European scientific societies for primary and secondary antithrombotic prevention in patients with cancer.
Authors and Affiliations
Magdalena Zaborowska, Sebastian Szmit, Cezary Szczylik
Keywords
Related Articles
- EP ID EP53106
- DOI -
- Views 233
- Downloads 0
Tuberus sclerosis
Kontrolowane placebo, z podwójnie ślepą próbą, prospektywne, randomizowane badanie skuteczności oktreotudu LAR w kontroli guza u chorych na guzy neuroendokrynne środkowej części prajelita z przerzutami: raport grupy badawczej PROMID
Wstęp: Analogi somatostatyny są wskazane w opanowywaniu objawów u chorych na żołądkowo-jelitowo-trzustkowe guzy neuroendokrynne (NETs). Zdolność analogów somatostatyny do kontrolowania wzrostu wysoko zróżnicowanych NETs...
Chemioterapia w guzach neuroendokrynnych układu pokarmowego (GEP-NEN)
Nowotwory neuroendokrynne układu pokarmowego w chwili rozpoznania choroby są w stadium rozsianym u ok. 2/3 chorych. Chemioterapia z użyciem schematu cisplatyna + etopozyd pozostaje standardem w przypadku zaawansowanych p...
Irreversible tyrosine kinase inhibitors of epidermal growth factor receptors family – a new, promising therapeutic strategy
Inhibitors of tyrosine kinase residues of epidermal growth factor receptor family (ErbB) have became a treatment of choice in many tumor types. However, even in the presence of predictive factors some patients completely...
Complications of palliative antiangiogenic therapy in patients with colorectal cancer
Introduction: Bevacizumab is an antiangiogenic drug used in the therapy of numerous solid tumours including colorectal adenocarcinoma. The efficacy and safety of bevacizumab has been demonstrated in many multicenter clin...